Eledon Pharmaceuticals/$ELDN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Eledon Pharmaceuticals
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
- Ticker
- $ELDN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 33
- Headquarters
- Irvine, United States
- Website
- eledon.com
ELDN Metrics
BasicAdvanced
$192M
-
-$0.99
0.96
-
Price and volume
Market cap
$192M
Beta
0.96
52-week high
$4.49
52-week low
$1.35
Average daily volume
869K
Financial strength
Current ratio
7.896
Quick ratio
7.565
Long term debt to equity
0.001
Total debt to equity
0.006
Profitability
Effective tax rate (TTM)
-0.04%
Management effectiveness
Return on assets (TTM)
-39.02%
Return on equity (TTM)
-110.71%
Valuation
Price to book
2.66
Price to tangible book (TTM)
4.83
Price to free cash flow (TTM)
-3.199
Free cash flow yield (TTM)
-31.26%
Free cash flow per share (TTM)
-0.739
Growth
Earnings per share change (TTM)
316.75%
3-year earnings per share growth (CAGR)
-51.59%
What the Analysts think about ELDN
Analyst ratings (Buy, Hold, Sell) for Eledon Pharmaceuticals stock.
Analyst projections of the future price of Eledon Pharmaceuticals stock.
ELDN Financial Performance
Revenues and expenses
ELDN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ELDN
Fund name | Fund size | $ELDN weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.